Does OSIMERTINIB Cause Malignant transformation? 109 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 109 reports of Malignant transformation have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.4% of all adverse event reports for OSIMERTINIB.
109
Reports of Malignant transformation with OSIMERTINIB
0.4%
of all OSIMERTINIB reports
19
Deaths
5
Hospitalizations
How Dangerous Is Malignant transformation From OSIMERTINIB?
Of the 109 reports, 19 (17.4%) resulted in death, 5 (4.6%) required hospitalization, and 1 (0.9%) were considered life-threatening.
Is Malignant transformation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 109 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Malignant transformation?
ETOPOSIDE (108)
MELPHALAN (95)
CYTARABINE (91)
CARMUSTINE (88)
CYCLOPHOSPHAMIDE (73)
PREDNISONE (69)
GEFITINIB (67)
VINCRISTINE (66)
DOXORUBICIN (61)
IFOSFAMIDE (60)
Which OSIMERTINIB Alternatives Have Lower Malignant transformation Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN